MA56535A - Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées - Google Patents

Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Info

Publication number
MA56535A
MA56535A MA056535A MA56535A MA56535A MA 56535 A MA56535 A MA 56535A MA 056535 A MA056535 A MA 056535A MA 56535 A MA56535 A MA 56535A MA 56535 A MA56535 A MA 56535A
Authority
MA
Morocco
Prior art keywords
hbv
vaccines
hepatitis
virus
self
Prior art date
Application number
MA056535A
Other languages
English (en)
Inventor
Daniel Boden
Helen Horton
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA56535A publication Critical patent/MA56535A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA056535A 2019-06-20 2020-06-19 Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées MA56535A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863961P 2019-06-20 2019-06-20
US202063006925P 2020-04-08 2020-04-08

Publications (1)

Publication Number Publication Date
MA56535A true MA56535A (fr) 2022-04-27

Family

ID=71833364

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056535A MA56535A (fr) 2019-06-20 2020-06-19 Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Country Status (7)

Country Link
US (1) US20220313815A1 (fr)
EP (1) EP3986458A1 (fr)
AU (1) AU2020298267A1 (fr)
CA (1) CA3143632A1 (fr)
MA (1) MA56535A (fr)
TW (2) TWI769467B (fr)
WO (1) WO2020255055A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
US12178921B2 (en) 2020-08-14 2024-12-31 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
WO2022150773A2 (fr) * 2021-01-11 2022-07-14 The Regents Of The University Of California Constructions d'arn activées par un ribozyme et leurs utilisations
EP4376883A4 (fr) * 2021-07-30 2025-07-16 Arcturus Therapeutics Inc Vaccins à arn
CN115960922A (zh) * 2021-10-09 2023-04-14 吴可行 自复制rna分子设计及其应用
US12115217B2 (en) 2022-11-18 2024-10-15 Trustees Of Boston University Self-replicating RNA and uses thereof
WO2025040709A1 (fr) * 2023-08-24 2025-02-27 BioNTech SE Systèmes et compositions comprenant des réplicases à amplification trans hautement actives
WO2025088152A1 (fr) 2023-10-27 2025-05-01 Ziphius Nv 5'utr modifiées

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
TWI575070B (zh) * 2011-07-12 2017-03-21 傳斯堅公司 Hbv聚合酶突變體
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
NZ747635A (en) 2016-03-28 2024-05-31 Ichor Medical Systems Inc Method and apparatus for delivery of therapeutic agents
ES2993107T3 (en) 2016-10-17 2024-12-23 Janssen Pharmaceuticals Inc Recombinant virus replicon systems and uses thereof
JP7788787B2 (ja) 2016-12-05 2025-12-19 ヤンセン ファーマシューティカルズ,インコーポレーテッド 遺伝子発現増強のための組成物および方法
GB201705765D0 (en) * 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd HBV vaccine
MA51311A (fr) * 2017-12-19 2020-10-28 Janssen Sciences Ireland Unlimited Co Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
CA3085492A1 (fr) * 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methodes et appareil pour l'administration de vaccins contre le virus de l'hepatite b (vhb)
JP2021506300A (ja) * 2017-12-19 2021-02-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー B型肝炎ウイルス(hbv)に対する免疫応答を誘導するための方法および組成物
EP3864027A1 (fr) * 2018-10-08 2021-08-18 Janssen Pharmaceuticals, Inc. Réplicons à base d'alphavirus pour l'administration d'agents biothérapeutiques

Also Published As

Publication number Publication date
AU2020298267A1 (en) 2022-02-17
CA3143632A1 (fr) 2020-12-24
TWI769467B (zh) 2022-07-01
TW202108598A (zh) 2021-03-01
US20220313815A1 (en) 2022-10-06
WO2020255055A1 (fr) 2020-12-24
EP3986458A1 (fr) 2022-04-27
TW202235428A (zh) 2022-09-16
TWI828168B (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
MA51311A (fr) Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
MA50520A (fr) Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb)
MA50524A (fr) Nouveaux indole-2-carboxamides à substitution amino-thiazole hautement actifs agissant contre le virus de l'hépatite b (vhb)
MA51292A (fr) Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb)
PH12019500788A1 (en) Engineered meganucleases specific for recgonition sequences in the hepatitis b virus genome
EP3668520A4 (fr) Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations
MA56534A (fr) Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb)
MA50335A (fr) Vaccins à acide nucléique contre des virus respiratoires
PT1685243E (pt) Linhas celulares aviárias imortalizadas para a produção de vírus
EP4324923A4 (fr) Inhibiteur d'arn pour inhiber l'expression de gène du virus de l'hépatite b et son application
EA201791343A1 (ru) Композиции и способы для конструирования вирусного генома in vitro
WO2011015656A3 (fr) Composition pour le traitement d'une infection par le virus de l'hépatite b
IL288019A (en) Preparations and methods for treating hepatitis b virus infection
WO2009039248A8 (fr) Méthodes de traitement d'une infection par un virus de la famille des flaviviridae et compositions pour le traitement d'une infection par un virus de la famille des flaviviridae
WO2010107739A3 (fr) Méthodes et compositions pour traiter l'infection par un virus de la famille des flaviviridae
MA51312A (fr) Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)
EP4022086C0 (fr) Compositions et procédés pour l'amplification et la détection de l'arn du virus de l'hépatite b, comprenant l'arn du vhb transcrit à partir de adnccc
ZA202305094B (en) Oligonucleotide and use thereof against hepatitis b virus and hepatitis d virus
IL281698A (en) Monomer and multimeric anti-hbv agents
DK4069729T3 (da) Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
LT4126932T (lt) Antikūno molekulės prieš bk virusą
MA56524A (fr) Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
IL313397A (en) Omni-103 CRISPR and RNA nuclease conjugates
HRP20090230T1 (hr) Replikacijski-defektni rna virusi kao cjepiva
IL290924A (en) Vaccines for hepatitis b virus